Tempus’ 3D Tumor Organoid (TO) Screens

Fixed panels:

• Antibody-drug conjugates (ADC) panels: ~25 TOs enriched for over-expression of key ADC cell surface protein targets: HER2, TROP2, Nectin4, and FRα.
• PanLung: ~25 non-small cell lung cancer (NSCLC) TOs enriched for a range of mutations, including pre-treated models.

Key insights:

• TO viability assessments via luminescence readouts
• Responses to standard of care (SOC) therapies, specific to indications, biomarkers, or both
• Molecular characterization of each organoid at baseline with Tempus xT & xR NGS assays (648 gene, full transcriptome)
• Bioinformatics analyses to inform molecular drivers of response or resistance, asset prioritization, and indication selection or validation 

Seamlessly synergize biomarkers uncovered with Tempus Explore.
Our expert data scientists and computational biologists leverage our vast real-world data (RWD) library to generate and further validate hypotheses across 1,000,000+ records with matched clinical data linked with genomic information.

Enrollment is open through March 31, 2025. Space is limited – complete the form now to secure your spot.